China-based XtalPi, Inc. has announced a research collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to deliver chemical matter with validated binding affinities and desirable property profiles. The collaboration was facilitated by Johnson & Johnson Innovation LLC.
Collaboration Details
Under the agreement, XtalPi will deliver validated small molecule hits that possess defined properties for a given target nominated by Janssen. XtalPi will leverage its comprehensive, end-to-end platform, Inclusive Digital Drug Discovery & Development (ID4), which integrates proprietary cloud-based computations and state-of-the-art wet lab capabilities. The aim is to significantly shorten the “Design-Make-Test-Analyze” (DMTA) cycle, thereby accelerating the drug discovery process.
Platform and Future Outlook
XtalPi’s ID4 platform is designed to optimize the efficiency and accuracy of drug discovery by combining advanced computational methods with experimental validation. This collaboration with Janssen marks a significant step in leveraging digital technologies to enhance the development of novel therapeutics. Financial details of the agreement were not disclosed.-Fineline Info & Tech
